AAPL299.77+1.76 (+0.59%) ▲|ABBV230.63+14.14 (+6.53%) ▲|ABT87.83-0.59 (-0.66%) ▼|ACN121.53-6.45 (-5.04%) ▼|ADBE193.54-1.63 (-0.83%) ▼|AMAT627.06+9.95 (+1.61%) ▲|AMD546.40+9.03 (+1.68%) ▲|AMGN342.18+4.58 (+1.36%) ▲|AMT177.24+1.19 (+0.68%) ▲|AMZN233.57-10.82 (-4.43%) ▼|AVGO394.92-16.43 (-3.99%) ▼|AXP337.15-0.86 (-0.25%) ▼|BA221.59-1.13 (-0.51%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG165.27-6.51 (-3.79%) ▼|BLK1,050.06-0.03 (0.00%) ▼|BMY54.35+0.35 (+0.64%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B490.10+0.64 (+0.13%) ▲|C145.74+2.68 (+1.87%) ▲|CAT1,016.41+30.59 (+3.10%) ▲|CL90.52+1.04 (+1.16%) ▲|CMCSA22.41-0.03 (-0.11%) ▼|COF199.29-2.24 (-1.11%) ▼|COP109.01+1.27 (+1.18%) ▲|COST950.35-1.10 (-0.12%) ▼|CRM149.09-2.69 (-1.77%) ▼|CSCO121.05+1.51 (+1.26%) ▲|CVS102.59+4.27 (+4.34%) ▲|CVX173.80+0.17 (+0.10%) ▲|DE603.46+14.22 (+2.41%) ▲|DHR175.83-1.34 (-0.76%) ▼|DIS102.88-1.01 (-0.97%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.68+0.02 (+0.01%) ▲|FDX329.82+4.84 (+1.49%) ▲|GD345.22-4.79 (-1.37%) ▼|GE357.640.00 (0.00%) ▼|GEV1,114.95+5.22 (+0.47%) ▲|GILD123.82+0.06 (+0.05%) ▲|GM82.58+3.29 (+4.15%) ▲|GOOG342.22-25.24 (-6.87%) ▼|GOOGL342.77-25.26 (-6.86%) ▼|GS1,094.90-1.66 (-0.15%) ▼|HD329.78-4.50 (-1.35%) ▼|HON231.08+2.07 (+0.90%) ▲|IBM246.19-2.92 (-1.17%) ▼|INTC140.02+6.03 (+4.50%) ▲|INTU258.80-8.20 (-3.07%) ▼|ISRG401.85-4.94 (-1.21%) ▼|JNJ230.89+2.50 (+1.09%) ▲|JPM330.36+5.14 (+1.58%) ▲|KO79.54+0.15 (+0.18%) ▲|LIN512.40+0.25 (+0.05%) ▲|LLY1,098.30-0.27 (-0.02%) ▼|LMT495.22-15.73 (-3.08%) ▼|LOW216.04-6.16 (-2.77%) ▼|LRCX394.19+5.15 (+1.32%) ▲|MA487.65-2.14 (-0.44%) ▼|MCD274.12-4.49 (-1.61%) ▼|MDLZ60.06-0.06 (-0.10%) ▼|MDT78.90-0.44 (-0.55%) ▼|META561.37-15.85 (-2.75%) ▼|MMM162.94+2.34 (+1.45%) ▲|MO69.98+0.86 (+1.24%) ▲|MRK113.73-0.15 (-0.13%) ▼|MS226.88+3.71 (+1.66%) ▲|MSFT371.46-7.94 (-2.09%) ▼|MU1,191.02+57.03 (+5.03%) ▲|NEE87.21+0.46 (+0.53%) ▲|NFLX74.12-3.26 (-4.22%) ▼|NKE43.52-1.68 (-3.72%) ▼|NOW93.18-1.86 (-1.96%) ▼|NVDA209.31-1.38 (-0.66%) ▼|ORCL178.82-5.47 (-2.97%) ▼|PEP141.71-0.31 (-0.22%) ▼|PFE25.11-0.10 (-0.38%) ▼|PG150.08-0.31 (-0.20%) ▼|PLTR122.33-6.14 (-4.78%) ▼|PM175.39-3.01 (-1.69%) ▼|QCOM228.57+2.46 (+1.09%) ▲|RTX181.93-3.67 (-1.98%) ▼|SBUX100.87+0.22 (+0.21%) ▲|SCHW91.86+0.16 (+0.17%) ▲|SO93.80+0.71 (+0.76%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.37+0.36 (+1.64%) ▲|TMO459.70-4.92 (-1.06%) ▼|TMUS180.80-0.87 (-0.48%) ▼|TSLA408.50+8.01 (+2.00%) ▲|TXN332.07+9.21 (+2.85%) ▲|UBER71.77+0.13 (+0.17%) ▲|UNH405.93+4.97 (+1.24%) ▲|UNP261.35+4.47 (+1.74%) ▲|UPS107.99+3.13 (+2.98%) ▲|USB58.85+0.71 (+1.21%) ▲|V330.32+3.08 (+0.94%) ▲|VZ45.65+0.28 (+0.62%) ▲|WFC83.42+1.22 (+1.48%) ▲|WMT117.70+0.52 (+0.44%) ▲|XOM137.76-0.05 (-0.04%) ▼|AAPL299.77+1.76 (+0.59%) ▲|ABBV230.63+14.14 (+6.53%) ▲|ABT87.83-0.59 (-0.66%) ▼|ACN121.53-6.45 (-5.04%) ▼|ADBE193.54-1.63 (-0.83%) ▼|AMAT627.06+9.95 (+1.61%) ▲|AMD546.40+9.03 (+1.68%) ▲|AMGN342.18+4.58 (+1.36%) ▲|AMT177.24+1.19 (+0.68%) ▲|AMZN233.57-10.82 (-4.43%) ▼|AVGO394.92-16.43 (-3.99%) ▼|AXP337.15-0.86 (-0.25%) ▼|BA221.59-1.13 (-0.51%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG165.27-6.51 (-3.79%) ▼|BLK1,050.06-0.03 (0.00%) ▼|BMY54.35+0.35 (+0.64%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B490.10+0.64 (+0.13%) ▲|C145.74+2.68 (+1.87%) ▲|CAT1,016.41+30.59 (+3.10%) ▲|CL90.52+1.04 (+1.16%) ▲|CMCSA22.41-0.03 (-0.11%) ▼|COF199.29-2.24 (-1.11%) ▼|COP109.01+1.27 (+1.18%) ▲|COST950.35-1.10 (-0.12%) ▼|CRM149.09-2.69 (-1.77%) ▼|CSCO121.05+1.51 (+1.26%) ▲|CVS102.59+4.27 (+4.34%) ▲|CVX173.80+0.17 (+0.10%) ▲|DE603.46+14.22 (+2.41%) ▲|DHR175.83-1.34 (-0.76%) ▼|DIS102.88-1.01 (-0.97%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.68+0.02 (+0.01%) ▲|FDX329.82+4.84 (+1.49%) ▲|GD345.22-4.79 (-1.37%) ▼|GE357.640.00 (0.00%) ▼|GEV1,114.95+5.22 (+0.47%) ▲|GILD123.82+0.06 (+0.05%) ▲|GM82.58+3.29 (+4.15%) ▲|GOOG342.22-25.24 (-6.87%) ▼|GOOGL342.77-25.26 (-6.86%) ▼|GS1,094.90-1.66 (-0.15%) ▼|HD329.78-4.50 (-1.35%) ▼|HON231.08+2.07 (+0.90%) ▲|IBM246.19-2.92 (-1.17%) ▼|INTC140.02+6.03 (+4.50%) ▲|INTU258.80-8.20 (-3.07%) ▼|ISRG401.85-4.94 (-1.21%) ▼|JNJ230.89+2.50 (+1.09%) ▲|JPM330.36+5.14 (+1.58%) ▲|KO79.54+0.15 (+0.18%) ▲|LIN512.40+0.25 (+0.05%) ▲|LLY1,098.30-0.27 (-0.02%) ▼|LMT495.22-15.73 (-3.08%) ▼|LOW216.04-6.16 (-2.77%) ▼|LRCX394.19+5.15 (+1.32%) ▲|MA487.65-2.14 (-0.44%) ▼|MCD274.12-4.49 (-1.61%) ▼|MDLZ60.06-0.06 (-0.10%) ▼|MDT78.90-0.44 (-0.55%) ▼|META561.37-15.85 (-2.75%) ▼|MMM162.94+2.34 (+1.45%) ▲|MO69.98+0.86 (+1.24%) ▲|MRK113.73-0.15 (-0.13%) ▼|MS226.88+3.71 (+1.66%) ▲|MSFT371.46-7.94 (-2.09%) ▼|MU1,191.02+57.03 (+5.03%) ▲|NEE87.21+0.46 (+0.53%) ▲|NFLX74.12-3.26 (-4.22%) ▼|NKE43.52-1.68 (-3.72%) ▼|NOW93.18-1.86 (-1.96%) ▼|NVDA209.31-1.38 (-0.66%) ▼|ORCL178.82-5.47 (-2.97%) ▼|PEP141.71-0.31 (-0.22%) ▼|PFE25.11-0.10 (-0.38%) ▼|PG150.08-0.31 (-0.20%) ▼|PLTR122.33-6.14 (-4.78%) ▼|PM175.39-3.01 (-1.69%) ▼|QCOM228.57+2.46 (+1.09%) ▲|RTX181.93-3.67 (-1.98%) ▼|SBUX100.87+0.22 (+0.21%) ▲|SCHW91.86+0.16 (+0.17%) ▲|SO93.80+0.71 (+0.76%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.37+0.36 (+1.64%) ▲|TMO459.70-4.92 (-1.06%) ▼|TMUS180.80-0.87 (-0.48%) ▼|TSLA408.50+8.01 (+2.00%) ▲|TXN332.07+9.21 (+2.85%) ▲|UBER71.77+0.13 (+0.17%) ▲|UNH405.93+4.97 (+1.24%) ▲|UNP261.35+4.47 (+1.74%) ▲|UPS107.99+3.13 (+2.98%) ▲|USB58.85+0.71 (+1.21%) ▲|V330.32+3.08 (+0.94%) ▲|VZ45.65+0.28 (+0.62%) ▲|WFC83.42+1.22 (+1.48%) ▲|WMT117.70+0.52 (+0.44%) ▲|XOM137.76-0.05 (-0.04%) ▼|
22.8 C
New York
Monday, June 22, 2026

Tag: cells

newssourceFORcompanyinformationcontent1marketreleases

Atnaujinti valstybės lūkesčiai „EPSO-G“: prioritetai – energetinė žalioji transformacija, jungtys, atsparumo ir saugumo didinimas bei sistemos lankstumas

Naujosios energetikos įmonių grupė „EPSO-G“ (toliau – Grupė) (įmonės kodas 302826889, registruotos buveinės adresas Laisvės pr. 10, Vilnius, Lietuva)

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma...

Adverse events were generally low-grade, transient, and readily manageable

Innovative Molecules Offer Good News in the Fight Against HIV and Other Viral Infections

INRS team is exploring the potential of saponins, a group of natural molecules found in many plants LAVAL, QC, July 3, 2025 /CNW/ - Innovative, nontoxic...

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...

Gwo Xi Stem Cell Company Powers Local Regenerative Medicine, Partners with Japan to Open a New Era

HSINCHU, July 3, 2025 /PRNewswire/ -- Gwo Xi Stem Cell Applied Technology Co., Ltd. (TPEx: 6704) is a clinical-stage cell therapy company headquartered in...

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...

SeaStar Medical Announces Positive Nasdaq Listing Determination

DENVER, July 02, 2025 (GLOBE NEWSWIRE) -- Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has received confirmation from The Nasdaq Stock Market that the Company has evidenced compliance with the minimum $2.5 million stockholders’ equity requirement and all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the previously disclosed listing matter has been closed.

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H)...

Weather RADAR Market Set to Hit Valuation of US$ 816.19 Million By 2033 | Astute Analytica

CHICAGO, July 2, 2025 /PRNewswire/ -- The global weather RADAR market was valued at US$ 158.43 million in 2024 and is projected to reach US$...

Weather RADAR Market Set to Hit Valuation of US$ 816.19 Million By 2033 | Astute Analytica

CHICAGO, July 2, 2025 /PRNewswire/ -- The global weather RADAR market was valued at US$ 158.43 million in 2024 and is projected to reach US$...

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID...

Invivyd Forms SPEAR (Spike Protein Elimination and Recovery) Study Group with Researches to Assess Effects of Monoclonal Antibody Therapy for Long COVID

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCells

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers